Flyvbjerg A, Jørgensen K D, Marshall S M, Orskov H
Pharmacological Department, NOVO-Nordisk, Gentofte.
Am J Physiol. 1991 Apr;260(4 Pt 1):E568-74. doi: 10.1152/ajpendo.1991.260.4.E568.
We investigated the effect of a somatostatin analogue octreotide (SMS) on the stimulatory effect of recombinant human growth hormone (hGH) on insulin-like growth factor I (IGF-I) generation and growth in hypophysectomized rats. Two weeks after hypophysectomy, treatment was given for 11 days with either saline, SMS (100 micrograms/day), hGH (140 micrograms/day), or hGH plus SMS. Compared with saline-injected controls, hGH stimulated body weight gain [1.1 +/- 0.7 vs. 40.9 +/- 0.8 (SE) g, P less than 0.001] and width of epiphysial cartilage (138.0 +/- 4.5 vs. 356 +/- 3.8 microns, P less than 0.001). Combined treatment with hGH and SMS significantly reduced both body weight gain (29.1 +/- 2.5 g, P less than 0.001) and width of epiphysial cartilage (315.3 +/- 5.8 microns, P less than 0.001) compared with the effects of hGH alone. During 11 days of hGH treatment, serum IGF-I increased from 22 +/- 5 to 1,288 +/- 92 micrograms/l (P less than 0.001) but increased only 40% (513 +/- 71 vs. 1,288 +/- 92 micrograms/l, P less than 0.001) when SMS was given in combination with hGH. In gastrocnemius muscle, heart, and lung, but not in liver, kidney, and brain, SMS suppressed organ weight increase when given both with and without hGH substitution. Thymus and gastrointestinal tract weight were significantly reduced in the group receiving SMS alone and tended to be reduced in the hGH-substituted group given SMS as well. Tissue IGF-I was increased in liver, lung, kidney, and heart with hGH treatment (P less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了生长抑素类似物奥曲肽(SMS)对重组人生长激素(hGH)刺激垂体切除大鼠胰岛素样生长因子I(IGF-I)生成及生长的影响。垂体切除两周后,分别用生理盐水、SMS(100微克/天)、hGH(140微克/天)或hGH加SMS进行为期11天的治疗。与注射生理盐水的对照组相比,hGH刺激体重增加[1.1±0.7 vs. 40.9±0.8(SE)克,P<0.001]以及骺软骨宽度增加(138.0±4.5 vs. 356±3.8微米,P<0.001)。与单独使用hGH的效果相比,hGH与SMS联合治疗显著降低了体重增加(29.1±2.5克,P<0.001)和骺软骨宽度(315.3±5.8微米,P<0.001)。在hGH治疗的11天中,血清IGF-I从22±5增加到1288±92微克/升(P<0.001),但当SMS与hGH联合使用时仅增加了40%(513±71 vs. 1288±92微克/升,P<0.001)。在腓肠肌、心脏和肺中,但不在肝脏、肾脏和大脑中,无论是否有hGH替代,SMS均抑制器官重量增加。单独接受SMS治疗的组中胸腺和胃肠道重量显著降低,在接受hGH替代且给予SMS的组中也有降低趋势。hGH治疗使肝脏、肺、肾脏和心脏中的组织IGF-I增加(P<0.01)。(摘要截断于250字)